Foundation for Mitochondrial Medicine

AA

A A
Foundation for Mitochondrial Medicine

Alzheimer’s Drug Discovery Foundation and Foundation for Mitochondrial Medicine Partner to Provide Grant for Drug Development for Novel Mitochondrial-Directed Therapies


ATLANTA, August 15, 2013 – The Alzheimer’s Drug Discover Foundation (ADDF) and the Foundation for Mitochondrial Medicine (FMM) announce a partnership to drive innovative translational research for mitochondrial dysfunction.  ADDF and FMM will provide grants in the range of $100,000 to $200,000 for a one-year duration with the possibility of follow-on funding.

Mitochondria dysfunction underlies many different diseases. The brain is particularly vulnerable to changes in energy use that occur with age or because of underlying disease pathology.  Novel therapies that can correct defects in mitochondria functioning have the potential to impact many different diseases – from early childhood genetic diseases to late-life neurodegenerative diseases such as Alzheimer’s disease.

Priority areas for the grant include the discovery and development of new drugs that alter mitochondria function; discovery and development of novel biomarkers of mitochondria dysfunction; validation of mitochondrial assays for drug discovery and development; and repurposing or screen existing drugs for activities related to mitochondria function.

Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Funding to biotechnology companies is typically made as a program-related investment. Deadline date for applications is September 5, 2013. Submission of a Letter of Intent (LOI) is required prior to August 22, 2013.

Applications will be confidentially reviewed by the ADDF, FMM and an external Scientific Review Committee.  Applications from biotechnology companies will also be reviewed by the ADDF’s external Business Advisory Board. Award winners will be publicly announced by spring 2014. All LOI and applications must be submitted electronically at www.alzdiscovery.org.  For further scientific or financial aspects of proposals, please contact Diana Shineman, PhD, Director of Scientific Affairs/ADDF, dshineman@alzdiscovery.org.  For more information on the
application process, contact Reena Vanjani, Grants Manager/ADDF,
rvanjani@alzdiscovery.org.

About the Alzheimer’s Drug Discovery Foundation (ADDF):  The mission of the ADDF  is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s diseases, related dementias and cognitive aging.  The ADDF has granted more than $62 million to fund nearly 415 Alzheimer’s drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information, visit www.AlzDiscovery.org.

About the Foundation for Mitochondrial Medicine (FMM):  The Foundation for Mitochondrial Medicine’s mission is to support the development of the most promising research and treatments for the many forms of mitochondrial disease.  Cures for mitochondrial diseases could impact cures for Autism, Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease among others.  For more information on FMM funded research such as functional MRI studies on cognitive fatigue and testing of new drug compounds, visit
www.mitochondrialdiseases.org

 

Media Contacts:
ADDF: Jayme Rubright, 212.901.8000, jrubright@alzdiscovery.org,
FMM:  Jennifer Grizzle, jennifer@theprstudio.com, 770.409.1152

Stay Connected with FMM

  • This field is for validation purposes and should be left unchanged.
Translate »